

Title (en)
PHARMACEUTICAL COMPOSITION IN UNIT FORM CONTAINING ACETYLSALICYLIC ACID AND CLOPIDOGREL HYDROGENOSULPHATE

Title (de)
ACETYLSALICYLSÄURE UND CLOPIDOGREL HYDROGENOSULFAT ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNG IN EINZELDOSISFORM

Title (fr)
COMPOSITION PHARMACEUTIQUE SOUS FORME UNITAIRE CONTENANT DE L'ACIDE ACETYLSALICYLIQUE ET DE L'HYDROGENOSULFATE DE CLOPIDOGREL

Publication
EP 1178809 A1 20020213 (FR)

Application
EP 00922737 A 20000425

Priority
• FR 0001086 W 20000425
• FR 9905497 A 19990430

Abstract (en)
[origin: WO0066130A1] The invention concerns a pharmaceutical composition containing in galenical unit form a combination of active principles with platelet antiaggregating activity consisting of acetylsalicylic acid and clopidogrel hydrogenosulphonate.

IPC 1-7
A61K 31/616; **A61P 9/00**; **A61P 9/10**

IPC 8 full level
A61K 9/20 (2006.01); **A61K 9/48** (2006.01); **A61K 31/4365** (2006.01); **A61K 31/60** (2006.01); **A61K 31/616** (2006.01); **A61K 47/04** (2006.01); **A61K 47/14** (2006.01); **A61K 47/26** (2006.01); **A61K 47/36** (2006.01); **A61K 47/38** (2006.01); **A61K 47/42** (2006.01); **A61P 3/10** (2006.01); **A61P 7/02** (2006.01); **A61P 9/00** (2006.01); **A61P 9/04** (2006.01); **A61P 9/06** (2006.01); **A61P 9/10** (2006.01); **A61P 9/14** (2006.01); **A61P 25/28** (2006.01); **A61P 41/00** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP KR)
A61K 9/20 (2013.01 - KR); **A61K 9/2077** (2013.01 - EP); **A61K 31/60** (2013.01 - EP); **A61K 31/616** (2013.01 - KR); **A61P 3/10** (2018.01 - EP); **A61P 7/02** (2018.01 - EP); **A61P 9/00** (2018.01 - EP); **A61P 9/04** (2018.01 - EP); **A61P 9/06** (2018.01 - EP); **A61P 9/10** (2018.01 - EP); **A61P 9/14** (2018.01 - EP); **A61P 25/28** (2018.01 - EP); **A61P 41/00** (2018.01 - EP); **A61P 43/00** (2018.01 - EP)

C-Set (source: EP)
1. **A61K 31/60** + **A61K 31/435**
2. **A61K 31/60** + **A61K 2300/00**

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 0066130 A1 20001109; AR 023789 A1 20020904; AU 4303600 A 20001117; BR 0010194 A 20020213; CA 2371231 A1 20001109; CN 1359294 A 20020717; CZ 20013887 A3 20020213; EA 200100959 A1 20020627; EE 200100559 A 20030217; EP 1178809 A1 20020213; FR 2792836 A1 20001103; FR 2792836 B3 20010727; HK 1041823 A1 20020726; HU P0202329 A2 20021028; IL 145648 A0 20020630; IS 6084 A 20010925; JP 2002543137 A 20021217; KR 20020005735 A 20020117; MX PA01011071 A 20020722; NO 20015295 D0 20011029; NO 20015295 L 20011221; NZ 514248 A 20030630; PL 351923 A1 20030630; SK 15542001 A3 20020205; TR 200103039 T2 20020121; UY 26131 A1 20001229

DOCDB simple family (application)
FR 0001086 W 20000425; AR P000102020 A 20000428; AU 4303600 A 20000425; BR 0010194 A 20000425; CA 2371231 A 20000425; CN 00807001 A 20000425; CZ 20013887 A 20000425; EA 200100959 A 20000425; EE P200100559 A 20000425; EP 00922737 A 20000425; FR 9905497 A 19990430; HK 02103639 A 20020514; HU P0202329 A 20000425; IL 14564800 A 20000425; IS 6084 A 20010925; JP 2000615014 A 20000425; KR 20017013830 A 20011029; MX PA01011071 A 20000425; NO 20015295 A 20011029; NZ 51424800 A 20000425; PL 35192300 A 20000425; SK 15542001 A 20000425; TR 200103039 T 20000425; UY 26131 A 20000428